A Novel Stimulation Protocol for Poor-Responder Patients: Combining the Stop GnRH-ag Protocol with Letrozole Priming and Multiple-Dose GnRH-ant: A Proof of Concept.
Adult
Animals
Ants
Aromatase Inhibitors
/ administration & dosage
Chorionic Gonadotropin
/ administration & dosage
Female
Fertilization in Vitro
/ methods
Gonadotropin-Releasing Hormone
/ antagonists & inhibitors
Hormone Antagonists
/ administration & dosage
Humans
Letrozole
/ administration & dosage
Ovulation Induction
/ methods
Pregnancy
Pregnancy Rate
Prospective Studies
Silver
Sperm Injections, Intracytoplasmic
/ methods
Treatment Outcome
Controlled ovarian hyperstimulation
GnRH-antagonist
POSEIDON
Poor responders
Stop protocol
Journal
Gynecologic and obstetric investigation
ISSN: 1423-002X
Titre abrégé: Gynecol Obstet Invest
Pays: Switzerland
ID NLM: 7900587
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
10
2020
accepted:
10
12
2020
pubmed:
25
3
2021
medline:
29
6
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
The objective of this study was to examine whether the combined Stop GnRH-agonist (GnRH-ag), letrozole priming, and multiple-dose GnRH-antagonist (GnRH-ant) protocol may improve in vitro fertilization/intracytoplasmic sperm injection cycle in poor ovarian responders (PORs). This was a historical cohort, proof of concept study under tertiary setting at University affiliated Medical Center. Five PORs fulfilling the POSEIDON Group 4 criteria were included. Number of oocytes retrieved, number of top-quality embryos (TQEs), and controlled ovarian hyperstimulation (COH) variables were the main outcome measures. The combined Stop GnRH-ag, letrozole priming, and multiple-dose GnRH-ant COH protocol revealed significantly higher number of follicles >13 mm on the day of hCG administration and higher number of oocytes retrieved, with non-significantly more TQEs and a reasonable clinical pregnancy rate. The combined Stop GnRH-ag, letrozole priming, and multiple-dose GnRH-ant COH protocol is a valuable tool in the armamentarium for treating POSEIDON Group 4 patients. Further large prospective studies are needed to elucidate its role in POR and to identify the specific characteristics of women (before initiating ovarian stimulation) that will aid both fertility specialists' counseling and their patients in adjusting the appropriate COH protocol.
Identifiants
pubmed: 33761501
pii: 000513669
doi: 10.1159/000513669
doi:
Substances chimiques
Aromatase Inhibitors
0
Chorionic Gonadotropin
0
Hormone Antagonists
0
Gonadotropin-Releasing Hormone
33515-09-2
Silver
3M4G523W1G
Letrozole
7LKK855W8I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-154Informations de copyright
© 2021 S. Karger AG, Basel.